Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast SurgeryStatus: open
17-149 - A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients With Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery
Treatment for Breast Cancer
This phase II trial studies how well biopsy of breast after chemotherapy works in predicting pathologic response in patients with stage II-IIIA breast cancer undergoing breast conserving surgery. Tumor tissue collected from biopsy before surgery may help to check if chemotherapy destroyed the breast cancer cells and may be compared to the tumor removed during surgery to check if they are the same. IRB Number 17-149
SponsorsThis trial is sponsored by NRG.
Interested in Clinical Trial?
Providers Associated With This Trial
- Donna Lynn Dyess, M.D.Breast/Endocrine SurgeonProfessor of Surgery
- Daniel G. Cameron, M.D.Medical Oncologist and HematologistAssociate Professor of Interdisciplinary Clinical Oncology
- Elesyia D. Outlaw, M.D.Radiation OncologistDirector of Women's Radiotherapy Program; Program Director of Brachytherapy Program; Associate Professor of Interdisciplinary Clinical Oncology